



(12) Translation of
european patent specification

(11) NO/EP 2441753 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 209/88 (2006.01)

A61K 31/343 (2006.01)

A61K 31/381 (2006.01)

A61K 31/403 (2006.01)

A61K 31/4439 (2006.01)

A61K 31/454 (2006.01)

A61K 31/4545 (2006.01)

A61K 31/496 (2006.01)

A61K 31/5377 (2006.01)

A61P 25/24 (2006.01)

A61P 25/28 (2006.01)

A61P 35/00 (2006.01)

A61P 35/02 (2006.01)

A61P 35/04 (2006.01)

A61P 43/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.07.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.03.30
(86)	European Application Nr.	10786195.7
(86)	European Filing Date	2010.06.09
(87)	The European Application's Publication Date	2012.04.18
(30)	Priority	2009.06.10, JP, 2009139691
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
(73)	Proprietor	Chugai Seiyaku Kabushiki Kaisha, 5-1, Ukima 5-chome, Kita-kuTokyo 115-8543, JP-Japan
(72)	Inventor	KINOSHITA Kazutomo, c/o Chugai Seiyaku Kabushiki Kaisha200 Kajiwara, Kamakura-shiKanagawa 247-8530, JP-Japan ASOH Kohsuke, c/o Chugai Seiyaku Kabushiki Kaisha200 Kajiwara, Kamakura-shiKanagawa 247-8530, JP-Japan FURUICHI Noriyuki, c/o Chugai Seiyaku Kabushiki Kaisha200 Kajiwara, Kamakura-shiKanagawa 247-8530, JP-Japan ITO Toshiya, c/o Chugai Seiyaku Kabushiki Kaisha200 Kajiwara, Kamakura-shiKanagawa 247-8530, JP-Japan KAWADA Hatsuo, c/o Chugai Seiyaku Kabushiki Kaisha200 Kajiwara, Kamakura-shiKanagawa 247-8530, JP-Japan ISHII Nobuya, c/o Chugai Seiyaku Kabushiki Kaisha200 Kajiwara, Kamakura-shiKanagawa 247-8530, JP-Japan SAKAMOTO Hiroshi, c/o Chugai Seiyaku Kabushiki Kaisha200 Kajiwara, Kamakura-shiKanagawa 247-8530, JP-Japan HONG WooSang, c/o C&C Research Laboratories146-141 ANNYEONG-DONG, HWASEONG-SIGYEONGGI-DO 445-380, KR-Sør-Korea PARK MinJeong, c/o C&C Research Laboratories146-141 ANNYEONG-DONG, HWASEONG-SIGYEONGGI-DO 445380, KR-Sør-Korea ONO Yoshiyuki, c/o Chugai Seiyaku Kabushiki Kaisha1-135 Komakado, Gotenba-shiShizuoka 412-8513, JP-Japan KATO Yasuharu, c/o Chugai Seiyaku Kabushiki Kaisha1-135 Komakado, Gotenba-shiShizuoka 412-8513, JP-Japan MORIKAMI Kenji, c/o Chugai Seiyaku Kabushiki Kaisha1-135 Komakado, Gotenba-shiShizuoka 412-8513, JP-Japan EMURA Takashi, c/o Chugai Seiyaku Kabushiki Kaisha1-135 Komakado, Gotenba-shiShizuoka 412-8513, JP-Japan OIKAWA Nobuhiro, c/o Chugai Seiyaku Kabushiki Kaisha200 Kajiwara, Kamakura-shiKanagawa 247-8530, JP-Japan

(74) Agent or Attorney Onsagers AS, Postboks 1813 Vika, 0123 OSLO, Norge

(54) Title **TETRACYCLIC COMPOUND**

(56) References
Cited: WO-A1-00/69856
 WO-A1-2008/051547
 WO-A2-2009/073620
 JP-A- 8 092 090

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. 9-etyl-6,6-dimetyl-8-(4-morfolin-4-yl-piperidin-1-yl)-11-okso-6,11-dihydro-5H-benzo[b]-karbasol-3-karboonitril eller salt eller solvat derav.

5

2. Medikament omfattende som aktiv ingrediens forbindelsen ifølge krav 1, eller et salt eller solvat derav.

10

3. ALK-inhibitor omfattende som en aktiv ingrediens forbindelsen ifølge krav 1, eller et salt eller solvat derav.

4. Farmsøytisk middel for profylakse eller behandlingen av kreft, kreftmetastase, depresjon eller kognitiv funksjonsforstyrrelse, omfattende som en aktiv ingrediens forbindelsen ifølge krav 1, eller et salt eller solvat derav.

15

5. Farmasøytisk sammensetning omfattende forbindelsen ifølge krav 1, eller et salt eller solvat derav, og en farmasøytisk akseptabel bærer/bærere.